Advice
Following an abbreviated submission
quetiapine prolonged-release tablet (Seroquel XL®) is accepted for use within NHS Scotland for the treatment of schizophrenia and manic episodes associated with bipolar disorder.
It is suitable for patients in whom quetiapine is an appropriate choice of antipsychotic. For equivalent doses it has similar or lower costs compared to immediate-release quetiapine.
Download detailed advice24KB (PDF)
Medicine details
- Medicine name:
- quetiapine fumerate (Seroquel XL)
- SMC ID:
- 433/07
- Indication:
- Schizophrenia in adults (18 years and over)
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Central nervous system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 10 November 2008